Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]N-methylspiperone
- Development stage
- Unknown
- Lead developer
- Johns Hopkins University
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[11C]N-methylspiperone (NMSP) is a radiopharmaceutical and small molecule used as a positron emission tomography (PET) imaging agent. It is a derivative of the antipsychotic drug spiperone, radiolabeled with the positron-emitting isotope carbon-11. NMSP acts as a high-affinity antagonist for dopamine D2-like receptors (including D2, D3, and D4) and serotonin 5-HT2A receptors. In clinical research, it is primarily used to quantify receptor density and occupancy in the brain, particularly in the striatum and extrastriatal regions. Unlike reversible ligands such as [11C]raclopride, NMSP is characterized as an 'irreversible' or slowly dissociating ligand during the timeframe of a PET scan, making it a robust tool for studying receptor availability in conditions like Parkinson's disease, schizophrenia, and various movement disorders.
- Other names
- 3-N-([11C]methyl)spiperoneN-[11C]methylspiperone[11C]-N-methylspiperone
02
Targets
HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on [11C]N-methylspiperone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]N-methylspiperone.